Metrics as of 10/13/2026, 06:50 PM (Berlin time), refresh in progress.
Generate Biomedicines Stock
Generate Biomedicines, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Michael T. Nally
- Employees
- 312
- Market cap
- $1.6 B
- IPO
- 27/02/2026
Generate Biomedicines, Inc. is a US-based company in the healthcare sector, operating within the biotechnology industry. Headquartered in Somerville, the company pioneers generative biology by leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core business model focuses…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Generate Biomedicines stock: price history
1D
-7.4%
1W
-15.7%
1M
-22.9%
6M
-2.9%
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
Not enough history for an assessment
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Generate Biomedicines
Analyst assessment of Generate Biomedicines
PRICE TARGET LOW
US$22.00
CONSENSUS
US$26.00
MEDIAN
US$26.00
PRICE TARGET HIGH
US$30.00
0
STRONG BUY
2
BUY
0
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 05/10/2026
Generate Biomedicines stock metrics
P/E
-12.24
P/B
3.65
EV/EBITDA
-12.76
RETURN ON EQUITY
-14.7%
NET MARGIN
-1,065.2%
DEBT/EQUITY
0.14
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
42.9%
FLOAT SHARES
55,051,623
AVG. DAILY VOLUME (30D)
1,170,069
Insider transactions (SEC)
ARNOLD FRANCES
Institutional holders
Comparable stocks
Frequently asked questions about Generate Biomedicines stock
What does Generate Biomedicines do?
Generate Biomedicines, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Michael T. Nally, the company employs around 312 people.
The IPO was on 27/02/2026; the stock trades on NASDAQ under the ticker GENB.
What do analysts say about Generate Biomedicines stock?
2 analysts rate the stock, the consensus is Buy (as of 05/10/2026).
The average price target is US$26.00, ranging from US$22.00 to US$30.00, with a median of US$26.00.
This is an external assessment, not a statement by Market Jury.
When does Generate Biomedicines report next?
The next earnings date is 05/11/2026.
Does Generate Biomedicines pay a dividend?
No, Generate Biomedicines currently does not pay a dividend.
Which stocks are comparable to Generate Biomedicines?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Generate Biomedicines stock analyzed?
Clicking "Analyze stock" lets five strategies assess Generate Biomedicines against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.